Rui Castro

@ruicastrohd.bsky.social

Associate Professor @FFULisboa & PI @iMedULisboa | Metabolic liver diseases pathophysiology, biomarkers & treatment | Scientific Committee member @EASL

2️⃣ translational studies on surpassing therapeutic resistance in liver cancer in press @jhepatology.bsky.social In CCA, cisplatin-induced INF2 degradation was identified as a mechanism of enhanced cisplatin resistance 👉https://journal-of-hepatology.eu/article/S0168-8278(25)00219-3/fulltext

Bild

📢EASL Studio today!👇 In the week celebrating #IWD2025, Saskia van Mil, Sara Della Torre & Münevver Demir will address mechanisms driving sex disparities in MASLD Tune in! 📺 🔗https://easl.eu/easl-studio-episode/s8e6/

Bild

🤩🤩🤩 Loved your presentation @dinatiniakos.bsky.social ! Great overview of where liver biopsy and pathology fits within the new MASLD nomenclature; and what the future holds with upcoming innovations! 👏🏼

Dina Tiniakos@dinatiniakos.bsky.social · 2y ago

@EASLnews.bsky.social in #Estoril 🇵🇹 from 2004 1️⃣st #NAFLD Monothematic Conference to 2025 #SLDsummit. Same place, same subject, 21 years apart. Time flies, #liver biopsy🔬remains central for steatohepatitis dx! @myueg.bsky.social @liverpath.bsky.social @aasld-heptoxsig.bsky.social

Happy to join Bluesky. My main priority will be to contribute building a community of patient-oriented liver lovers. I also want to post about humanism, creativity, photos…. I was playing this morning to create a logo for the liver community. Cheers to all.

Bild